Tresiba (insulin degludec) is a prescription drug that’s used to manage high blood sugar in people with diabetes. Tresiba’s cost may depend on your dosage, your health insurance, and the pharmacy you ...

Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...

Tresiba (insulin degludec) may not be safe to use while pregnant or breastfeeding. Factors including the form you take or the condition being treated may determine whether you should use the drug ...

Concern about overnight hypoglycemic events drives decision-making for patients with type 1 diabetes. For persons with type 1 diabetes (T1D) fear of the overnight hypoglycemic event drives care ...

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will ...

Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW) approved ...

Novo Nordisk (NVO) said new data from a phase 3a trial showed that more people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with its own once-daily therapy ...